ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/CD47
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/CD47
6
trial(s) found.
NCT05957536
Advanced
Phase 1
Recruiting
A Phase 1, Open-label Dose Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3L-001 Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors. (
D3L-001-100
)
bispecific ERBB2/CD47 antibody
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
NCT05002127
Advanced
Phase 2 / Phase 3
Recruiting
A Phase 2/3 Study of Evorpacept (ALX148) in Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06) (
AT148006
)
CD47-blocking fusion protein
Gastric adenocarcinoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
VIC
3168 - Clayton - Monash Medical Centre
NA
4215 - Southport - Icon Cancer Centre Southport
NCT04643002
Haem
Phase 1 / Phase 2
Recruiting
Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol (
ACT16482
)
anti-CD38 monoclonal antibody
glucocorticoid
immunomodulatory imide drug
+ CD47-blocking fusion protein
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
ACTRN12622000856718
Haem
Phase 1 / Phase 2
Not yet recruiting
A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study assessing safety and tolerability of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma (
ISB-1442-101
)
bispecific CD38/CD47 antibody
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
QLD
4215 - Southport - Gold Coast University Hospital
4217 - Benowa - Pindara Private Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT05330429
Advanced
Phase 2
Terminated
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (
ELEVATE-CRC
)
anti-CD47 monoclonal antibody
anti-VEGF monoclonal antibody
Colorectal cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2228 - Miranda - Southside Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NCT05200013
Advanced
Phase 1
Completed
A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT7104 in Patients With Advanced Solid Tumours (
BAT-7104-002-CR
)
bispecific PD-L1/CD47 antibody
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
WA
6009 - Nedlands - One Clinical Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (3)
Not yet recruiting (1)
Terminated (1)
Completed (1)
Recruitment Country and State
NSW (5)
VIC (5)
QLD (2)
WA (2)
TAS (1)
SA (1)
Phase
Phase 1 (2)
Phase 1 / Phase 2 (2)
Phase 2 (1)
Phase 2 / Phase 3 (1)
Trial Type
Advanced (4)
Haem (2)
Cancer Therapy Class
CD47
100%
ERBB2
33%
CD38
33%
VEGFR2
17%
ROCK2
17%
TGF-beta
17%
cereblon
17%
VEGF
17%
PD-1/PD-L1
17%
PD-L1
17%
Facility
2109 - North Ryde - Macquarie University Hospital (2)
3004 - Melbourne, Southbank - Alfred Health (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
3168 - Clayton - Monash Medical Centre (1)
4215 - Southport - Icon Cancer Centre Southport
2500 - Wollongong - Wollongong Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
3066 - Epping - Northern Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
7000 - Hobart - Royal Hobart Hospital (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
2228 - Miranda - Southside Cancer Care Centre (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
6009 - Nedlands - One Clinical Research (1)
Cancer Type
Cancer
Solid tumour
Gastrointestinal cancer
Haematological malignancy
Multiple myeloma
Plasma cell disorder
Gastric adenocarcinoma
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Oesophageal cancer
Thoracic cancer
Upper gastrointestinal cancer
Colorectal cancer
Lower gastrointestinal cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy